Benitec Biopharma Ltd ADR (BNTC)
Benitec Biopharma Ltd ADR is a depositary receipt linked to Benitec Biopharma Inc., a clinical-stage biotechnology company focused on developing genetic medicines. The company’s core research platform, Silence and Replace, is a DNA-directed RNA interference approach that combines RNA interference with gene therapy. Benitec is using this technology to support therapies intended to deliver sustained gene silencing together with replacement of the normal gene sequence after a single treatment. One of its lead programs is BB-301, an AAV-based gene therapy being developed for the treatment of dysphagia associated with oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. is headquartered in Hayward, California, while the listed security trades on NASDAQ under the ticker BNTC.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BNTC
|
$9.79
|
-19.0% Downside
|
Overvalued
|
$25.80
|
113.6% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
September 22, 2026
|
-10.0x
|
2.3x
|
—
|
411.2 M
|
231.1 M
|
0.2%
|
52.2%
|
65.7
|
—
|
47.7%
|
